Why It's Fierce: IDM is our top pick in the resurgent cancer vaccine field. The company's Cell Drugs combine two cell groups to create a customized therapy for strengthening the body's immune response to cancerous antigens. With five drugs in late stage clinical development, IMD has reached the make or break stage of its business model. We're optimistic the company will make good on the promise of cancer vaccines.
What to look for in 2003: Results of a Phase III ovarian cancer vaccine study should be announced shortly.